Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of “Moderate Buy” by Brokerages

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has earned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $13.6250.

Several analysts recently commented on VNDA shares. B. Riley boosted their price target on Vanda Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, December 31st. Wall Street Zen raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. UBS Group reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday, January 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, December 17th.

Vanda Pharmaceuticals Stock Performance

NASDAQ:VNDA opened at $7.78 on Friday. The firm has a market capitalization of $459.80 million, a PE ratio of -5.48 and a beta of 0.60. The company has a quick ratio of 3.10, a current ratio of 3.12 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals has a 12-month low of $3.81 and a 12-month high of $9.60. The firm has a 50-day moving average price of $6.87 and a 200 day moving average price of $5.49.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.07). Vanda Pharmaceuticals had a negative net margin of 39.70% and a negative return on equity of 16.82%. The company had revenue of $56.26 million during the quarter, compared to the consensus estimate of $58.73 million. Research analysts anticipate that Vanda Pharmaceuticals will post -1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. increased its holdings in Vanda Pharmaceuticals by 456.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 5,328 shares in the last quarter. CWM LLC boosted its stake in Vanda Pharmaceuticals by 424.6% in the second quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 7,575 shares in the last quarter. Quarry LP bought a new stake in shares of Vanda Pharmaceuticals during the third quarter worth $53,000. SG Americas Securities LLC acquired a new stake in shares of Vanda Pharmaceuticals in the fourth quarter valued at $95,000. Finally, Boothbay Fund Management LLC bought a new position in shares of Vanda Pharmaceuticals in the third quarter valued at about $72,000. 88.14% of the stock is owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.